Aclarion, Inc. (ACON)
NASDAQ: ACON · IEX Real-Time Price · USD
0.291
0.00 (0.00%)
At close: Jul 2, 2024, 4:00 PM
0.295
+0.004 (1.34%)
After-hours: Jul 2, 2024, 6:56 PM EDT
Company Description
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States.
It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.
Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Aclarion, Inc.
Country | United States |
Founded | 2008 |
IPO Date | Apr 22, 2022 |
Industry | Health Information Services |
Sector | Healthcare |
Employees | 4 |
CEO | Brent Ness |
Contact Details
Address: 8181 Arista Place, Ste 100 Broomfield, Colorado 80021 United States | |
Phone | 833 275 2266 |
Website | aclarion.com |
Stock Details
Ticker Symbol | ACON |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $4.35 |
CIK Code | 0001635077 |
CUSIP Number | 655187102 |
ISIN Number | US6551872012 |
Employer ID | 47-3324725 |
SIC Code | 8071 |
Key Executives
Name | Position |
---|---|
Brent Ness | Chief Executive Officer, President and Director |
Dr. Jeffrey John Thramann M.D. | Executive Chairman |
John Lorbiecki | Chief Financial Officer |
Ryan Bond | Chief Strategy Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 26, 2024 | 8-K | Current Report |
Jun 24, 2024 | QUALIF | Filing |
Jun 20, 2024 | 1-A/A | Filing |
Jun 18, 2024 | 8-K | Current Report |
Jun 11, 2024 | 1-A | Filing |
May 15, 2024 | 10-Q | Quarterly Report |
Apr 29, 2024 | 8-K | Current Report |
Apr 12, 2024 | 8-K | Current Report |
Mar 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Mar 28, 2024 | 10-K | Annual Report |